tradingkey.logo
tradingkey.logo

Lilly's Mounjaro Showed Cardiovascular Protection In Head-To-Head Trial

ReutersJul 31, 2025 10:49 AM

- Eli Lilly and Co LLY.N:

  • ELI LILLY: MOUNJARO SHOWED CARDIOVASCULAR PROTECTION IN HEAD-TO-HEAD TRIAL, REINFORCING BENEFIT IN PATIENTS WITH TYPE 2 DIABETES, HEART DISEASE

  • ELI LILLY: MOUNJARO MET PRIMARY OBJECTIVE OF NON-INFERIORITY VERSUS. TRULICITY WITH 8% LOWER RATE OF MACE-3 EVENTS

  • ELI LILLY: MOUNJARO WAS ASSOCIATED WITH 16% LOWER RATE OF ALL-CAUSE DEATH COMPARED TO TRULICITY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI